Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Investindustrial on its acquisition of Carl von Linnékliniken Group.
Mandate

Vinge advised Investindustrial on its acquisition of Carl von Linnékliniken Group.

November 30, 2020 Employment and Benefits Commercial Agreements Intellectual Property M&A

Carl von Linnékliniken Group is a leading fertility treatment clinic based in Uppsala offering various treatments such as IVF, IUI and gamete donation.

Investindustrial Growth Holdings S.à r.l. is an investment group with €11 billion of raised fund capital and focuses on taking control positions in medium-sized companies in Europe.

Vinge’s team consisted of responsible partner Matthias Pannier and associates Stina Bengtsson, Olivia Belding (M&A), Christoffer Nordin (Regulatory), Sofia Bergenstråhle (Intellectual Property), Veronika Garemark (Employment), Karl-Hugo Engdahl (GDPR) and Nathalie Hughes (Project Assistance).

 

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

 Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025